SecBot SecBot
PRESS-RELEASE ·Filed Jun 22, 2026

NRXP

NRx Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This expanded access approval is a modest positive for NRX-101's development pathway but does not change the binary risk of the ongoing SPARC-TMS pivotal trial. Traders should watch for enrollment updates and eventual topline data from the trial, which will determine the drug's commercial viability. No immediate revenue impact is expected.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.90
T+0 close · Jun 22, 2026 · via day close
Latest settled
−12.82%
T+60 · $3.40
Vs SPY
−14.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $3.90entry
  2. T+1 · 5mo ago −3.59%α −2.14% · $3.76
  3. T+5 · 5mo ago −4.36%α −2.29% · $3.73
  4. T+20 · 4mo ago +9.49%α +9.63% · $4.27
  5. T+60 · 2mo ago −12.82%α −14.57% · $3.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals announced FDA approval of an Expanded Access Protocol for NRX-101 (D-cycloserine/lurasidone) to augment Transcranial Magnetic Stimulation (TMS) in patients with Treatment-Resistant Depression. The company will initially charge only for shipping and data collection costs, not for the investigational drug, while a pivotal trial (SPARC-TMS) is underway. This is a procedural regulatory step that provides compassionate access but does not change the drug's approval status or provide new efficacy data.

Key Facts

  • FDA approved an Intermediate Population Expanded Access Protocol for NRX-101 to augment accelerated TMS in Treatment-Resistant Depression.
  • NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone, with Breakthrough Therapy Designation for suicidal bipolar depression.
  • Company will initially charge only for shipping and FDA-required data collection costs, not for the investigational drug.
  • Pivotal trial SPARC-TMS is ongoing in civilian and military treatment facilities.
  • NRX-100 (preservative-free IV ketamine) has Fast Track Designation for suicidal ideation in depression.

Financial Impact

No financial terms disclosed; company charging only shipping and data costs initially.

Risk Factors

  • Expanded access does not guarantee eventual FDA approval or commercial success.
  • Pivotal trial (SPARC-TMS) may fail to meet endpoints, which would severely impact valuation.
  • Compounded D-cycloserine competition exists, though company claims quality advantages.
  • Clinical-stage biopharma with no approved products and limited cash runway.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3315163

Track record

22 reports on NRXP

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026